Abcellera Biologics Inc reports a Return on Equity (ROE) of -15.35%.

What is ABCL's dividend yield?

Abcellera Biologics Inc offers a dividend yield of 0.00%.

What is ABCL's Quality Score?

Our AI rates ABCL's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ABCL?

Our AI Timing Score for ABCL is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ABCL belong to?

Abcellera Biologics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Abcellera Biologics Inc (ABCL) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

ABCL AI Analysis Summary

Our AI summary for ABCL: Abcellera Biologics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -15.35%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ABCL

Abcellera Biologics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 99

USD 5.71

0.02 (0.35%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-15.4%

ROE

-11.0%

ROA

0.00%

Div Yield

ABCELLERA BIOLOGICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 5.71 Price 0.02 (0.35%) Day Change	NEWS SCORE: 99

ABCL, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

38%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	99
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	5.71
PBV / Sector	1.85 / 5.20
Earning Per Share	-0.47

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	34.38 M GREAT
Average 1W Daily Value	27.56 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-181.75 / 98.71
NPM Average (%) / Sector	-258.76 / -1,721.76
NPM Change Average (%) / Sector	-326.13 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-11.01 / 27.02
ROA Average (%) / Sector	-6.66 / -368.17
ROA Change Average (%) / Sector	-45.44 / 5,404.12
ROE (%) / Sector	-15.35 / 3.47
ROE Average (%) / Sector	-9.15 / 6.51
ROE Change Average (%) / Sector	-44.48 / 2,128.13
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:25
Symbol	ABCL
Name	ABCELLERA BIOLOGICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	305.38 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	1,737.59 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 150 W 4th Avenue, Vancouver, BC, Canada, V5Y 1G6

Phone: 604 559 9005

Website: https://www.abcellera.com

Employees: 562

Sector: Healthcare >> Biotechnology

Description: AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.